Filing Details
Larimar Therapeutics, Inc. (NASDAQ:LRMR) filed a Form 8-K with the Securities and Exchange Commission on June 29, 2026, disclosing a material event.
8k filedNASDAQ:LRMR
Larimar Therapeutics, Inc. (LRMR) Reports Material Event to SEC
Filing Details Larimar Therapeutics, Inc. (NASDAQ:LRMR) filed a Form 8-K with the Securities and Exchange Commission on June 29, 2026, disclosing a material event. Market Context…
Market Context
Larimar Therapeutics, Inc.'s stock currently trades at $3.20 with a market capitalization of $343.6M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Larimar Therapeutics, Inc.'s stock.
All SEC filings for Larimar Therapeutics, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View LRMR Stock Page
Frequently Asked Questions
Where can I read LRMR's SEC filings?
Browse all filings on our LRMR SEC filings page.
What types of SEC filings does Larimar Therapeutics, Inc. file?
Public companies like Larimar Therapeutics, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.